Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12.
Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
User rating: 0.00% ( 0 
The Complete List Of Wilshire 5000 Stocks
Future Market Returns = Dividend Yield + Earnings Growth +/- Change In P/E Ratio
USD/JPY Making A Bullish N Pattern Through Chuvashov Fork
Ebay Rises As Morgan Stanley Double Upgrades On Payments Shakeup
The Pension Crisis Gets A Catchy Name: “Silver Tsunami”
